Influence of lead on cAMP-response element binding protein (CREB) and its implications in neurodegenerative disorders

2024-10-1

New metabolites of 2-ethylhexyl salicylate in human urine after simulated real-life dermal sunscreen application

2024-10-1

Ochratoxin A-induced DNA damage triggers G2 phase arrest via hMLH1-p53-p21 signaling pathway in human gastric epithelium immortalized cells in vitro

2024-10-1

Flavopiridol inhibits oocyte maturation, reduces oocyte quality and blocks cumulus cell function

2024-9-13

Editorial Board

2024-9-12

P05-20 A new large-scale benchmark knowledge graph leveraging the comparative toxicogenomics database

2024-9-1

P19-85 Alternative approaches to chemical risk assessment: challenging the current animal-based threshold approach

2024-9-1

P01-25 Comparative toxicology and pharmacology of covalent and noncovalent NRF2 activators in human macrophages

2024-9-1

CEC04-03 Exposure and risk assessment of plant protection products

2024-9-1

LP-37 Surveillance of pharmaceutical and transformation compounds in coastal waters of the Iberian Peninsula

2024-9-1

P02-29 Predicting drug-induced cardiac contractility alterations in a 3D beating heart-on-chip platform

2024-9-1

P06-25 The plasma metabolome of Genistein and Daidzein in rats

2024-9-1

P02-30 Generation and evaluation of a historical control database for the creation of assay acceptance criteria for a comparative in vitro hepatic enzyme assay

2024-9-1

P09-13 Methylmercury induces visual deficits of zebrafish embryos involving in dysregulation of gene expression in the retina

2024-9-1

LP-11 In silico metabolomic, cytotoxicity, mutagenicity, and carcinogenicity prediction of givinostat, a histone deacetylase inhibitor

2024-9-1

P20-10 Embracing regulatory compliance: Genetox meets generation SEND

2024-9-1

P12-11 Understanding the impact of a real-life mixture of poly- and perfluorinated compounds (PFAS) on the liver metabolism: insights from a dynamic 3D in vitro model

2024-9-1

P03-03 Quantitative in vitro to in vivo extrapolation (QIVIVE) for liver-induced thyroid toxicity risk assessment

2024-9-1

P01-75 Between-laboratory reproducibility of the modified STE to identify UN GHS Category 1 surfactants

2024-9-1

P05-04 Development of an open-source high throughput QSAR-parameterized PBTK prediction model workflow using httk, OPERA and the KNIME Analytics Platform

2024-9-1

P01-04 Extracts from different next generation product platforms show less potential to induce oxidative stress than extracts from cigarettes in human coronary artery endothelial cells (HCAECs) in vitro

2024-9-1

P02-03 Comparison of biological effects on mouse tracheal epithelial cells cultured at the Air-Liquid Interface: a study of cigarette smoke and heated tobacco product aerosol

2024-9-1

OS03-01 Utilization of human cardiac microtissues for 3D modelling of myocardial hypertrophy

2024-9-1

S22-01 Update on the science program of the international collaboration on cosmetics safety

2024-9-1

S17-02 Exposure and effect markers during firefighting activities – Danish intervention studies

2024-9-1

LP-49 Deriving tolerable intakes for data-poor medical device extractables: 3-Prop-2-en-1-yl propanedioate as a case study

2024-9-1

P23-18 Classical photovoltaic semiconductors leverage their catalytic properties to influence the molecular regulation mechanism of immune lung injury by interfering with mitochondrial electron transport

2024-9-1

P21-24 Arsenic in hair and nails of pet dogs as biomarkers of exposure to inorganic pollution from a gold mining area

2024-9-1

P21-35 Cardiorespiratory effects of indoor ozone exposure during sleep and the influencing factors: a prospective study among adults in China

2024-9-1

P21-65 Androgenic and anti-androgenic effects of nanoplastics

2024-9-1

P19-83 Employing QSAR modeling for regulatory assessment of TiO2 nanoparticle safety

2024-9-1

P19-10 Evaluating reliability and relevance of in vitro toxicity studies on micro- and nanoplastics

2024-9-1

P19-27 Effect of per- and polyfluoroalkyl substances (PFAS) on neurodevelopment: evaluation based on the TRAEC strategy in a systematic review context

2024-9-1

LP-04 In vivo metabolic behavior of nanobiomaterials: bridging the gap between nanostructures and nanosafety

2024-9-1

P18-11 Determination and analysis of γ-hydroxybutyric acid in blood by MPFC-QuEChERS with GC-Q-TOF/MS

2024-9-1

P13-03 Comparative study of mutagenic/antimutagenic and genotoxic/antigenotoxic activities of ethanolic and aqueous extracts prepared from Arbutus unedo fruits

2024-9-1

CEC01-05 Utilizing omics for AOPs: from de novo development and AOP refinement to biomarkers of effect

2024-9-1

P10-24 The impact of zinc oxide nanoparticles on various biochemical markers in seminal plasma

2024-9-1

CEC03-03 Clinical Safety issues

2024-9-1

P06-20 OMICs approaches linking effects of endocrine disrupters on developing rat hippocampus with impaired memory function in adult offspring and human stem cell-derived in vitro models

2024-9-1

P07-04 Biomarkers of arsenical vesicant lewisite ocular exposure in an in vivo rabbit model and effective countermeasures by dexamethasone

2024-9-1

P07-17 Recommendation of health-based biological guidance value for aluminium and its inorganic compounds for workers and the general population

2024-9-1

P01-06 Validating multi-ion channel inhibition assays following best practice considerations

2024-9-1

P01-54 New fluorescent probes for quick assessment of drug induced liver injury effects on bile canaliculi dynamism and albumin expression

2024-9-1

P01-36 Proeryptotic effects of non-functionalized polystyrene nanoparticles with different diameters

2024-9-1

P01-39 Mitochondrial toxicity screening to support the R&D crop protection pipeline

2024-9-1

OS02-06 Leveraging in silico binding affinity, in vitro bioactivity, and chemical structure to develop machine learning models for predicting in vivo toxicity

2024-9-1

P01-64 Approaches to mitigate known safety liabilities of immunomodulatory (IMiDs) drugs used in heterobifunctional degraders

2024-9-1

S25-02 ViCoG DB – a cross company control repository

2024-9-1

S24-02 Biomarkers of neurodevelopmental effect can reduce uncertainty when assessing the risks of thyroid disrupting chemicals

2024-9-1